NCT05904730View on ClinicalTrials.gov

Phase I Clinical Trials Investigating the Potential Efficacy of Axitinib in Patients With a BRCA 1/2 Mutations

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 11, 2023

Primary Completion Date

November 9, 2024

Study Completion Date

December 26, 2024

Conditions

Breast CancerOvarian CancerBreast NeoplasmsOvarian NeoplasmsBRCA MutationHER2-positive Breast CancerHER2-negative Breast CancerHER-2 Protein Overexpression

Interventions

DRUG

Axitinib

The starting dose of axitinib is 5 mg twice daily by mouth with meals. (reception is desirable at the same time every day)

Trial Locations (2)

49102

Trials TEAM, Dnipro

04107

Trials TEAM, Kyiv

All Listed Sponsors

lead

Lynkcell Europe

OTHER